^
Association details:
| Biomarker: | CXCR4 positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | balixafortide (POL 6326) (CXCR4 antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Balixafortide (a CXCR4 antagonist) plus eribulin in HER2 negative metastatic breast cancer: Dose-response analysis of efficacy from phase I single-arm trial.
Published date:
05/28/2020
Excerpt:
At entry, all 56 women (age range 33−82 years) were HER2-negative (IHC and/or FISH), CXCR4 positive. A consistent dose response effect for B + E was suggested in heavily pretreated pts with HER2 negative MBC across all efficacy endpoints....patients from Part II also included in EC because they received the B dose selected for EC (5.5mg/kg)...table.
Secondary therapy:
eribulin mesylate
DOI:
10.1200/JCO.2020.38.15_suppl.e15209
Trial ID:
Source:
Title:
Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial
Published date:
10/01/2018
Excerpt:
This is the first trial to investigate a CXCR4 antagonist in MBC. The tolerability profile and promising anti-tumor activity observed with B + E in this Phase I study warrants further investigation as well as exploration of additional combinations of B with other anti-cancer therapies.
Secondary therapy:
eribulin mesylate
DOI:
https://doi.org/10.1093/annonc/mdy272.277
